Arteriosclerosis remains the principal cause of myocardial infarction, stroke, and peripheral vascular disease in developed societies. Although the proliferation and de-differentiation of vascular smooth muscle cells (VSMC) is critical for the development of the arteriosclerotic lesion, the molecular mechanisms regulating these events are poorly understood. The long-term objectives are to define the molecular mechanisms regulating the growth and differentiation of vascular smooth muscle cells. Previously, they have identified and characterized a novel zinc-finger transcription factor named SmLIM that is highly and preferentially expressed in VSMC. Other members of this group of proteins have been shown to play essential roles in the development, growth, and differentiation of specific cell types. Thus, they hypothesize that SmLIM plays a similar role in VSMC. This proposal aims to investigate the role of SmLIM in regulating the state of VSMC differentiation and to define the molecular mechanisms regulating its preferential pattern of expression in VSMC. To assess the role of SmLIM in regulating the VSMC phenotype, they will establish stable clones overexpressing SmLIM in the sense and antisense orientations. They will then assess clonal characteristics such as growth, contractility, and expression of various markers of differentiation to determine SmLIM function in VSMC. SmLIM is highly and preferentially expressed in VSMC. Gene transcription is regulated by the interaction of specific DNA sequences (cis-acting elements) and their cognate binding proteins (trans-acting factors). Thus, they plan to identify and characterize the cis-acting elements and trans-acting factors important in regulating SmLIM expression. The proposed work will allow them to understand the importance of SmLIM in regulating VSMC growth and differentiation. Furthermore, identification of VAMC-specific cis- and trans-acting factors will be crucial to the future success of efforts to restrict the expression of foreign genes to the blood vessel wall for gene therapy of vascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
7K08HL003747-03
Application #
6182742
Study Section
Special Emphasis Panel (ZHL1-CSR-Y (M1))
Project Start
1998-07-01
Project End
2003-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
3
Fiscal Year
2000
Total Cost
$123,120
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02115
Hamik, Anne; Jain, Mukesh K (2010) PLDing a case for angiogenesis. Blood 116:1194-6
Feinberg, Mark W; Wara, Akm Khyrul; Cao, Zhuoxiao et al. (2007) The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J 26:4138-48
SenBanerjee, Sucharita; Lin, Zhiyong; Atkins, G Brandon et al. (2004) KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med 199:1305-15
Feinberg, Mark W; Watanabe, Masafumi; Lebedeva, Maria A et al. (2004) Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem 279:16388-93
Feinberg, Mark W; Lin, Zhiyong; Fisch, Sudeshna et al. (2004) An emerging role for Kruppel-like factors in vascular biology. Trends Cardiovasc Med 14:241-6
Feinberg, Mark W; Shimizu, Koichi; Lebedeva, Maria et al. (2004) Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res 94:601-8
Banerjee, Sucharita Sen; Feinberg, Mark W; Watanabe, Masafumi et al. (2003) The Kruppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. J Biol Chem 278:2581-4
Sibinga, Nicholas E S; Feinberg, Mark W; Yang, Hongyuan et al. (2002) Macrophage-restricted and interferon gamma-inducible expression of the allograft inflammatory factor-1 gene requires Pu.1. J Biol Chem 277:16202-10
Gray, Susan; Feinberg, Mark W; Hull, Sarah et al. (2002) The Kruppel-like factor KLF15 regulates the insulin-sensitive glucose transporter GLUT4. J Biol Chem 277:34322-8
Watanabe, Masafumi; Layne, Matthew D; Hsieh, Chung-Ming et al. (2002) Regulation of smooth muscle cell differentiation by AT-rich interaction domain transcription factors Mrf2alpha and Mrf2beta. Circ Res 91:382-9

Showing the most recent 10 out of 14 publications